Letter by Liu and Chen Regarding Article, “Unruptured Brain Arteriovenous Malformations: Primary ONYX Embolization in ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-Eligible Patients”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
In their recent article, Singfer et al1 investigated the outcomes of unruptured brain arteriovenous malformations (uBAVM) treated with primary embolization using ethylene vinyl alcohol (ONYX). The authors concluded that ONYX embolization alone or combined with stereotactic radiosurgery (SRS) achieved a high occlusion rate in uBAVM. Although we read this study with great interest, a series of questions arose.
First, the authors stated that 35 patients received therapy of endovascular embolization (EE) followed by SRS. However, there was no data concerning the exact time interval between EE and SRS in their article.1 The authors should have given this information. If we knew the exact time, this might …